NCT03046589View on ClinicalTrials.gov

DP13 SAD & MAD in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 6, 2017

Primary Completion Date

March 14, 2018

Study Completion Date

March 27, 2018

Conditions
Safety and Tolerability
Interventions
DRUG

DP13

dose escalation

DRUG

placebo

control to dose-escalation

Trial Locations (1)

LS2 9LH

Covance Clinical Research Unit Ltd, Leeds

Sponsors

Lead Sponsor

Damian Pharma AG

Collaborators (1)

Covance
All Listed Sponsors
collaborator

Covance

INDUSTRY

collaborator

Foundation for Therapeutic Research, Lausanne

UNKNOWN

collaborator

Insel Gruppe AG, University Hospital Bern

OTHER

lead

Damian Pharma AG

INDUSTRY